Merck CEO Rob Davis said the drugmaker has evolved beyond Keytruda, with more than 20 potential blockbuster launches over the next five years.
Merck CEO says new pipeline is built to offset Keytruda’s eventual patent expiration
No Comments1 Views
Trending
- Joc Pederson’s latest leadoff HR moves him closer to Rangers’ record
- The ‘Last batting title by MLB team’ quiz
- Ukraine war sparked race for countries to build spy satellites, space-tech CEO says
- Target appoints its first chief AI officer as big retailers bet on AI
- Manus to return as independent company after China forced Meta to unwind $2 billion deal
- Trump wants to split the MMR vaccine. Experts say that’s unlikely — and comes with consequences
- Democrats clash again in Minnesota and Wisconsin primaries as big midterm races take shape
- Trump says NYC pied-à-terre tax ‘must be stopped,’ eyes federal block
